Recent research has highlighted Brg1 as a promising therapeutic target for addressing pathological conditions such as myocardial hypertrophy and heart failure (Bevilacqua et al., 2014; Kidder et al., 2009; Ma et al., 2023; Li et al., 2024). This evidence concerns the gene SMARCA4 and cardiac hypertrophy.